Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sanofi Net Income Off 26 Percent In Second Quarter

By Mike Botta | July 31, 2018

Q2 2018 Change Change 
at CER
H1 2018 Change Change 
at CER
IFRS net sales reported  €8,176m  -5.7% +0.1% €16,074m  -7.2% -0.1%
IFRS net income reported  €762m  -26.2% – €1,778m  -73.6%(2) –
IFRS EPS reported  €0.61  -25.6% – €1.42  -73,4%(2) –
Business net income(1) €1,558m  -7.9% +0.4% €3,156m  -9.4% +0.4%
Business EPS(1) €1.25  -6.7% +1.5% €2.53  -8.3% +1.4%

Sanofi reported that net sales were €8,176 million, down 5.7 percent on a reported basis, up 0.1percent(3) at constant exchange rates (CER) and down 2.5 percent at CER/CS (4).

Sanofi Genzyme sales up 14.1 percent at CER/CS (4) (33.1 percent at CER) driven by Dupixent and consolidation of Bioverativ. Vaccines sales were down 15.7 percent reflecting high basis for comparison and expected Pentaxim supply constraint in China.

Consumer Health Care (CHC) sales increased 4.1 percent supported by growth in Europe and Emerging Markets(5). Diabetes and Cardiovascular(6) (DCV) Global Business Unit (GBU) sales were down 15.6 percent; global Diabetes franchise sales declined 11.9 percent, confirming an expected trend for the year, according to the company. Emerging Markets sales(5) increased 5.2 percent with double-digit growth in China.

“In the second quarter, we achieved significant milestones in building our new Rare Blood Disorder franchise and the successful continued execution of the global roll-out of Dupixent,” Olivier Brandicourt, Sanofi chief executive officer, commented regarding the 2Q results. “As the impact from the U.S. losses of exclusivity peaked in the second quarter, the growth of our diversified businesses largely compensated for these headwinds. We look forward to entering a new growth phase led by our increasing focus on Specialty Care and our leadership positions in Emerging Markets and Vaccines.”

2018 business earnings per share (EPS) guidance narrowed
  • Second-quarter 2018 business EPS(1) up 1.5 percent at CER to €1.25.
  • Second-quarter 2018 International Financial Reporting Standards (IFRS) EPS was €0.61 (-25.6%).
  • Business EPS(1) in 2018 now expected to grow 3 percent to 5 percent at CER(7) barring unforeseen major adverse events.
  • Currency impact on 2018 business EPS is estimated to be around -6 percent applying the average July exchange rates.
Key achievements in sustaining innovation in R&D
  • Sanofi completed the acquisition of Ablynx in May, internalizing the innovative Nanobody platform.
  • Positive CHMP recommendation for Cablivi for aTTP(8).
  • Phase 1/2a data on BIVV001, an extended factor VIII therapy, demonstrated half-life of 37 hours.
  • A phase 2/3 study is being initiated on venglustat, an oral glucosylceramide synthase (GCS) inhibitor, in ADPKD(9).
  • Positive phase 3 trial evaluating Dupixent to treat moderate-to-severe atopic dermatitis in adolescents.
  • Priority review granted in the U.S. to cemiplimab for the treatment of CSCC(10).
  • Zynquista (sotagliflozin) accepted for review by the FDA in type 1 diabetes.
  • Praluent ODYSSEY OUTCOMES results submitted to the FDA and EMA in Q2.

For the complete Sanofi 2Q 2018 earnings press release, click here.
___________________________________________________________________

References:

(1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure.
(2) Excluding Animal Health gain on disposal, first-half IFRS net income was down 22.6 percent and first-half IFRS EPS was down 22.4 percent
(3) Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated
(4) Constant Structure: Adjusted for Bioverativ acquisition 
(5) In June, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of Cablivi (caplacizumab) in the European Union for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi was developed by Ablynx, a Sanofi Company.
(6) DCV: Diabetes and Cardiovascular
(7) 2017 business EPS was €5.52 
(8) Acquired thrombotic thrombocytopenic purpura 
(9) Autosomal Dominant Polycystic Kidney Disease
(10) Cutaneous Squamous Cell Carcinoma

Note: Exchange rate on July 31, 2018: €1 = $1.17

(Source: Sanofi-Aventis Groupe)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE